COST action B25 - Physiologically based pharmaco-toxico-kinetics and dynamics: expert meeting on "From models to individual patients" (from in silico to bedside)
Abstract
Different topics were selected and discussed in relation to the main focus, especially: Antiepileptic drugs - pediatric modelling and simulation. Taking patients adherence into account in M and S.
Thiopurines as anticancer drugs. Simulations using mechanistic model: Individual risk assessment.
EMI-CD-European modeling initiative combating complex diseases. Role of Biosimulation and European BioSim Network in Drug Research and Development.
Anticoagulation drugs- modeling of blood coagulation and the application to clinical decision making. TDM of gentamicin in neonates critically ill.
After definition of the organ safety criterion and software implementation, simulations were performed in order to assess the individual risk which could involve a dose adjustment.